Table 3.
Meta-analysis of FGFR1 and prognosis in NSCLC patients
| Categories | Study population (reference) | Meta-analysis model | HR (95% CI) | I2 (%) | Ph | P-value |
|---|---|---|---|---|---|---|
| Overall survival | ||||||
| Overall | 13 (7–10,15–17,20–23,26,28) | Fixed | 1.30 (1.13–1.50) | 3.8 | 0.409 | <0.001 |
| NSCLC only | 7 (8,9,15–17,21,28) | Fixed | 1.25 (1.03–1.51) | 39.4 | 0.129 | 0.024 |
| SCC only | 7 (7,8,10,16,20,22,26) | Fixed | 1.31 (1.06–1.61) | 0 | 0.802 | 0.012 |
| Asian | 2 (18,28) | Fixed | 1.76 (1.16–2.66) | 0 | 0.695 | 0.008 |
| Non-Asian | 11 (7–10,15–17,20,22,23,26) | Fixed | 1.25 (1.07–1.45) | 0 | 0.44 | 0.005 |
| FISH analysis | 9 (7,8,15–17,20,22,23,28) | Fixed | 1.37 (1.16–1.61) | 0 | 0.621 | <0.001 |
| qPCR analysis | 2 (9,10) | Fixed | 1.04 (0.75–1.44) | 0 | 0.439 | 0.621 |
| Large study (n.300) | Fixed | 1.27 (1.01–1.60) | 0 | 0.052 | 0.042 | |
| Disease-free survival | ||||||
| Overall | 4 (7,8,20,28) | Random | 1.43 (0.96–2.12) | 54.3 | 0.087 | 0.075 |
| NSCLC only | 1 (8) | – | 1.46 (0.76–2.81) | – | – | .0.05 |
| SCC only | 4 (7,8,16,28) | Random | 1.37 (0.89–2.09) | 56.5 | 0.075 | 0.152 |
Note: P-value for heterogeneity, based on Q-test.
Abbreviations: NSCLC, non-small-cell lung cancer; HR, hazard ratio; CI, confidence interval; SCC, squamous cell carcinoma; FISH, fluorescence in situ hybridization; qPCR, quantitative polymerase chain reaction.